Inhibition of SCAP or SREBPs, either pharmacologically or genetically, has been found to significantly suppress tumor growth in various cancer models, suggesting that SCAP/SREBPs could be promising metabolic targets for cancer prevention and therapy [19,20]. The gene discussed is SCAP; the disease is cancer.